BRAF Exon 15 Mutation
Associated Genetic Biomarkers
BRAF Exon 15 Mutation is present in 3.57% of AACR GENIE cases, with colon adenocarcinoma, cutaneous melanoma, melanoma, thyroid gland papillary carcinoma, and lung adenocarcinoma having the greatest prevalence .
BRAF Exon 15 Mutation serves as an inclusion eligibility criterion in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial that contains BRAF Exon 15 Mutation as an inclusion criterion, 1 is phase 2 (0 open).
Significance of BRAF Exon 15 Mutation in Diseases
BRAF is altered in 32.54% of melanoma patients with BRAF Exon 15 Mutation present in 28.02% of all melanoma patients .
BRAF Exon 15 Mutation is an inclusion criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains BRAF Exon 15 Mutation and melanoma as inclusion criteria, 1 is phase 2 (0 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.